Kezar Life Sciences Stock Three Year Return

KZR Stock

USD 7.47 0.07 0.95%

Kezar Life Sciences fundamentals help investors to digest information that contributes to Kezar Life's financial success or failures. It also enables traders to predict the movement of Kezar Stock. The fundamental analysis module provides a way to measure Kezar Life's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Kezar Life stock.

Other Current Liab Total Assets

This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Kezar Life Sciences Company Three Year Return Analysis

Kezar Life's Tree Year Return shows the total annualized return generated from holding a fund or ETFs for the last three years. The return measure includes capital appreciation, losses, dividends paid, and all capital gains distributions. This return indicator is considered by many investors to be solid measures of fund mid-term performance.

Three Year Return

(Mean of Monthly Returns - 1)

X

100%

More About Three Year Return | All Equity Analysis

Kezar Three Year Return Driver Correlations

Understanding the fundamental principles of building solid financial models for Kezar Life is extremely important. It helps to project a fair market value of Kezar Stock properly, considering its historical fundamentals such as Three Year Return. Since Kezar Life's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Kezar Life's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Kezar Life's interrelated accounts and indicators.

	Total Assets	Total Stockholder Equity	Net Tangible Assets	Net Debt	Retained Earnings	Accounts Payable	Net Receivables	Capital Surpluse	Total Liab	Total Current Assets	Common Stock	Property Plant Equipment	Net Invested Capital	Net Working Capital	Short Term Investments	Deferred Long Term Liab	Capital Stock	Current Deferred Revenue	Short Term Debt	Long Term Debt	Long Term Debt Total
Total Assets		0.99	0.91	-0.39	-0.85	0.6	0.65	0.91	-0.18	1.0	0.97	0.57	0.99	0.98	0.9	-0.35	0.92	-0.89	0.85	0.42	0.49
Total Stockholder Equity	0.99		0.91	-0.3	-0.83	0.58	0.61	0.89	-0.34	0.99	0.97	0.62	1.0	0.97	0.86	-0.32	0.9	-0.86	0.82	0.39	0.46
Net Tangible Assets	0.91	0.91		-0.22	-0.97	0.85	0.82	1.0	-0.27	0.91	0.93	0.59	0.93	0.91	0.83	-0.68	0.92	-0.93	0.89	0.72	0.74
Net Debt	-0.39	-0.3	-0.22		0.18	-0.05	0.08	-0.22	-0.47	-0.4	-0.29	-0.11	-0.31	-0.33	-0.23	-0.02	-0.27	0.34	-0.12	0.02	0.03
Retained Earnings	-0.85	-0.83	-0.97	0.18		-0.93	-0.89	-0.99	0.13	-0.85	-0.89	-0.49	-0.85	-0.85	-0.82	0.76	-0.93	0.94	-0.93	-0.77	-0.84
Accounts Payable	0.6	0.58	0.85	-0.05	-0.93		0.89	0.87	-0.05	0.6	0.69	0.35	0.61	0.6	0.61	-0.92	0.77	-0.8	0.82	0.89	0.94
Net Receivables	0.65	0.61	0.82	0.08	-0.89	0.89		0.85	0.04	0.64	0.69	0.33	0.63	0.67	0.76	-0.79	0.77	-0.76	0.89	0.83	0.85
Capital Surpluse	0.91	0.89	1.0	-0.22	-0.99	0.87	0.85		-0.22	0.9	0.92	0.56	0.92	0.9	0.84	-0.7	0.93	-0.94	0.91	0.74	0.76
Total Liab	-0.18	-0.34	-0.27	-0.47	0.13	-0.05	0.04	-0.22		-0.18	-0.23	-0.45	-0.32	-0.21	-0.03	0.04	-0.1	0.09	-0.02	-0.05	0.04
Total Current Assets	1.0	0.99	0.91	-0.4	-0.85	0.6	0.64	0.9	-0.18		0.97	0.56	0.99	0.98	0.9	-0.34	0.92	-0.89	0.85	0.41	0.48
Common Stock	0.97	0.97	0.93	-0.29	-0.89	0.69	0.69	0.92	-0.23	0.97		0.54	0.97	0.95	0.87	-0.4	0.97	-0.91	0.9	0.43	0.61
Property Plant Equipment	0.57	0.62	0.59	-0.11	-0.49	0.35	0.33	0.56	-0.45	0.56	0.54		0.62	0.46	0.22	-0.26	0.36	-0.35	0.33	0.26	0.28
Net Invested Capital	0.99	1.0	0.93	-0.31	-0.85	0.61	0.63	0.92	-0.32	0.99	0.97	0.62		0.98	0.86	-0.37	0.91	-0.88	0.83	0.44	0.49
Net Working Capital	0.98	0.97	0.91	-0.33	-0.85	0.6	0.67	0.9	-0.21	0.98	0.95	0.46	0.98		0.95	-0.36	0.94	-0.92	0.87	0.44	0.48
Short Term Investments	0.9	0.86	0.83	-0.23	-0.82	0.61	0.76	0.84	-0.03	0.9	0.87	0.22	0.86	0.95		-0.38	0.92	-0.9	0.91	0.48	0.52
Deferred Long Term Liab	-0.35	-0.32	-0.68	-0.02	0.76	-0.92	-0.79	-0.7	0.04	-0.34	-0.4	-0.26	-0.37	-0.36	-0.38		-0.49	0.6	-0.57	-0.98	-0.83
Capital Stock	0.92	0.9	0.92	-0.27	-0.93	0.77	0.77	0.93	-0.1	0.92	0.97	0.36	0.91	0.94	0.92	-0.49		-0.96	0.95	0.53	0.68
Current Deferred Revenue	-0.89	-0.86	-0.93	0.34	0.94	-0.8	-0.76	-0.94	0.09	-0.89	-0.91	-0.35	-0.88	-0.92	-0.9	0.6	-0.96		-0.9	-0.65	-0.68
Short Term Debt	0.85	0.82	0.89	-0.12	-0.93	0.82	0.89	0.91	-0.02	0.85	0.9	0.33	0.83	0.87	0.91	-0.57	0.95	-0.9		0.6	0.8
Long Term Debt	0.42	0.39	0.72	0.02	-0.77	0.89	0.83	0.74	-0.05	0.41	0.43	0.26	0.44	0.44	0.48	-0.98	0.53	-0.65	0.6		0.77
Long Term Debt Total	0.49	0.46	0.74	0.03	-0.84	0.94	0.85	0.76	0.04	0.48	0.61	0.28	0.49	0.48	0.52	-0.83	0.68	-0.68	0.8	0.77

Click cells to compare fundamentals

Although Three Year Fund Return indicator can give a sense of overall fund mid-term potential, it is recommended to compare fund performances against other similar funds, ETFs, or market benchmarks for the same 3 year interval.

Competition

Predict Kezar Life

Kezar Return On Tangible Assets

Return On Tangible Assets

(0.48)

At this time, Kezar Life's Return On Tangible Assets are relatively stable compared to the past year.

Based on the latest financial disclosure, Kezar Life Sciences has a Three Year Return of 0.0%. This indicator is about the same for the Biotechnology average (which is currently at 0.0) sector and about the same as Health Care (which currently averages 0.0) industry. This indicator is about the same for all United States stocks average (which is currently at 0.0).

Kezar Three Year Return Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Kezar Life's direct or indirect competition against its Three Year Return to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Kezar Life could also be used in its relative valuation, which is a method of valuing Kezar Life by comparing valuation metrics of similar companies.

Kezar Life is currently under evaluation in three year return category among its peers.

Kezar Life ESG Sustainability

Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Kezar Life's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Kezar Life's managers, analysts, and investors.

Environmental

Governance

Social

Kezar Fundamentals

	Return On Equity	-0.51
	Return On Asset	-0.28
	Operating Margin	(14.22) %
	Current Valuation	(76.97 M)
	Shares Outstanding	7.3 M
	Shares Owned By Insiders	14.79 %
	Shares Owned By Institutions	63.90 %
	Number Of Shares Shorted	83.71 K
	Price To Earning	(9.34) X
	Price To Book	0.41 X
	Price To Sales	7.79 X
	Revenue	7 M
	EBITDA	(99.25 M)
	Net Income	(101.87 M)
	Cash And Equivalents	306.84 M
	Cash Per Share	4.49 X
	Total Debt	18.93 M
	Debt To Equity	0.04 %
	Current Ratio	39.64 X
	Book Value Per Share	25.77 X
	Cash Flow From Operations	(81.64 M)
	Short Ratio	0.93 X
	Earnings Per Share	(13.12) X
	Target Price	14.5
	Number Of Employees	58
	Beta	0.22
	Market Capitalization	54.5 M
	Total Asset	221.24 M
	Retained Earnings	(350.76 M)
	Working Capital	189.21 M
	Current Asset	74.47 M
	Current Liabilities	2.18 M
	Net Asset	221.24 M

About Kezar Life Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Kezar Life Sciences's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Kezar Life using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Kezar Life Sciences based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Please read more on our fundamental analysis page.

Pair Trading with Kezar Life

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Kezar Life position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Kezar Life will appreciate offsetting losses from the drop in the long position's value.

Moving together with Kezar Stock

0.76

EWTX

Edgewise Therapeutics

Pair Corr

Moving against Kezar Stock

0.57	MRK	Merck Company Fiscal Year End 6th of February 2025	Pair Corr
0.51	LTRN	Lantern Pharma	Pair Corr
0.5	HLN	Haleon plc	Pair Corr
0.5	TAK	Takeda Pharmaceutical	Pair Corr
0.46	ELAN	Elanco Animal Health	Pair Corr

The ability to find closely correlated positions to Kezar Life could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Kezar Life when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Kezar Life - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Kezar Life Sciences to buy it.

The correlation of Kezar Life is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Kezar Life moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Kezar Life Sciences moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Kezar Life can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

Additional Tools for Kezar Stock Analysis

When running Kezar Life's price analysis, check to measure Kezar Life's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Kezar Life is operating at the current time. Most of Kezar Life's value examination focuses on studying past and present price action to predict the probability of Kezar Life's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Kezar Life's price. Additionally, you may evaluate how the addition of Kezar Life to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC